Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients

Abstract

BACKGROUND Diabetes is a serious public health concern in China, with 30% of patients developing retinopathy, and diabetic macular edema (DME) having the biggest impact on vision. High blood glucose level can cause retinal cell hypoxia, thus promoting vascular endothelial growth factor (VEGF) formation and increasing vascular permeability, which induces DME. Moreover, cell hypoxia can accelerate the rate of apoptosis, which leads to the aging of patients. In severe cases, optic cell apoptosis or retinal fibrosis and permanent blindness may occur. AIM To investigate and compare the efficacy, mechanism, and differences between two anti-VEGF drugs (Compaq and ranibizumab) in DME patients. METHODS Ninety-six patients with DME who attended our hospital from April 2018 to February 2020 were included and randomly divided into two groups (Compaq group and ranibizumab group). The groups received vitreal cavity injections of 0.5 mg Compaq and 0.5 mg ranibizumab, respectively, once a month. The best corrected visual acuity (BCVA), intraocular pressure (IOP), macular retinal thickness (CMT), macular choroidal thickness (SFCT), foveal no perfusion area (FAZ), superficial capillary density, deep capillary density, treatment effect, and adverse reactions were compared before and after treatment and between the two groups. RESULTS Before treatment and 1-mo post-treatment, there was no statistically significant difference in the estimated BCVA in both groups ( P > 0.05). BCVA decreased in the Compaq group 3 mo after treatment, and the difference was statistically significant ( P < 0.05). Before treatment, and 1 mo and 3 mo post-treatment, there was no statistically significant difference in the estimated IOP in either group ( P > 0.05). Before treatment and 1-mo post-treatment, there was no statistically significant difference in the estimated CMT, SFCT, or FAZ in either group ( P > 0.05). CMT and SFCT values decreased in the Compaq group 3 mo post-treatment, and the difference was statistically significant ( P < 0.05). Before treatment, and 1 mo and 3 mo post-treatment, there were no statistically significant differences in vascular density in the shallow or deep capillary plexi of the fovea, parafovea, or overall macular area between the two groups ( P > 0.05). Marked efficient, effective, and invalid rates were 70.83% and 52.08%, 27.08% and 39.58%, and 2.08% and 8.33% in the Compaq and ranibizumab groups, respectively. The differences between the two groups were statistically significant ( P < 0.05). CONCLUSION Anti-VEGF drugs can effectively improve CMT and SFCT, without affecting microcirculation, thus providing an effective and safe treatment for patients with DME.

Predictive Value of Magnetic Resonance Imaging in Risk Stratification and Molecular Classification of Endometrial Cancer

“…Although the characteristic imaging markers of each subtype are useful for predicting patient prognosis and improving treatment strategies, our study revealed no significant differences in MRI parameters related to TP53 mutation. The TP53 gene mutation can promote the expression of vascular endothelial growth factor (VEGF), which can increase the permeability of blood vessels while inducing the growth of tumor blood vessels [ 42 ]. However, our study showed no significant association between TP53 mutation and MRI-detectable changes in angiogenesis.…”

The value of multimodal functional magnetic resonance imaging in differentiating p53abn from p53wt endometrial carcinoma

“…Moreover, Vermij et al (35) showed that the expression level of human epidermal growth factor receptor-2 (Her-2) is highly correlated with p53abn-type EC, and the overexpression of Her-2 can cause abnormality in EC cell proliferation. The TP53 gene mutation and the overexpression of Her-2 can promote the expression of vascular endothelial growth factor, which can increase the permeability of blood vessels while inducing the growth of tumour blood vessels (36), causing the release of some proteins. In addition, Meng et al (37) used APTw to identify cervical cancers of different pathological types and grades, and found that a certain amount of proteins and peptidesmay bereleased into the surrounding microenvironment during the process of tumour tissue necrosis.…”

Consensus on managing center-involving diabetic macular edema in Hong Kong: perspective

“…Anti-VEGF agents prevent the activation of VEGF receptors on endothelial cells and thus stop vascular endothelial hyperplasia from developing, thereby counteracting DME pathogenesis. 24 Current guidelines recommend monthly monitoring during the first 6 months of anti-VEGF treatment. 1,4 Monitoring should continue thereafter because worsening VA and CST rebound are common.…”